Spero Therapeutics (SPRO) FCF Margin (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly FCF Margin came in at 66.34% in Q4 2025, up 4493558.0% YoY from N/an in Q4 2024, and up 99.8% on a QoQ basis from 33350.0% in Q1 2025.
Spero Therapeutics (SPRO) FCF Margin (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 10 years of FCF Margin data on file, last reported at 66.34% in Q4 2025.
- Quarterly FCF Margin rose 4493558.0% year-over-year to 66.34% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 57.53% (up 38083.0% YoY) and the FY2025 annual result came in at 100.19%, up 621895.0% from the prior year.
- FCF Margin rose to 66.34% in Q4 2025, from 33350.0% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 19635.38% in Q3 2024 to a low of 45001.92% in Q4 2024.
- A 5-year average of 4215.78% and a median of 197.93% in 2021 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2021 — FCF Margin soared 5539267 bps — and 2024, when it plunged 4506157 bps.
- Tracing SPRO's FCF Margin over 5 years: stood at 219.81% in 2021, then grew by 21 bps to 265.17% in 2022, then sank by 78 bps to 59.65% in 2023, then sank by 75543 bps to 45001.92% in 2024, then surged by 100 bps to 66.34% in 2025.
- The last three FCF Margin figures came in at 66.34% (Q4 2025), 33350.0% (Q1 2025), and 45001.92% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,148.84% |
| Dec 31, 2025 | -66.34% |
| Mar 31, 2025 | -33,350.00% |
| Dec 31, 2024 | -45,001.92% |
| Sep 30, 2024 | 19,635.38% |
| Jun 30, 2024 | -183.82% |
| Mar 31, 2024 | 4,241.43% |
| Dec 31, 2023 | 59.65% |
| Sep 30, 2023 | 62.48% |
| Jun 30, 2023 | -683.51% |
| Mar 31, 2023 | -5,763.68% |
| Dec 31, 2022 | 265.17% |
| Sep 30, 2022 | -88.45% |
| Jun 30, 2022 | -2,570.65% |
| Mar 31, 2022 | -11,426.32% |
| Dec 31, 2021 | 219.81% |
| Sep 30, 2021 | -699.44% |
| Jun 30, 2021 | -321.81% |
| Mar 31, 2021 | -212.04% |
| Sep 30, 2020 | -56,092.11% |